Tarsus Pharmaceuticals, Inc. (TARS) Tops Q1 EPS by 14c, reaffirms product guidance

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q1 EPS of ($0.16), $0.14 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $162 million versus the consensus estimate of $153.12 million.

Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Truist says US banks cautiously optimistic on deposit growth
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO